Recent Trends in GLP-1 Use and Spending in Medicare Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, new data from the Centers for Medicare & Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions
It offers a gentle alternative for super-responders, those managing conditions like PCOS, or anyone simply trying to avoid debilitating side effects while navigating a broken system marked by high costs and shortages
In combination, they support collagen organization, reduced inflammation, and restored biomechanical strength, particularly in post-surgical or strain-induced injury models
Sermorelin may support sleep quality in some patients because growth hormone release is closely tied to deep sleep and recovery
A Note on Skin Lightening Injections Using high-dose injectable glutathione for skin bleaching is a trend with major red flags